Mahasweta Gooptu retweeted
Venetoclax plus Inotuzumab Ozogamicin for Relapsed and Refractory Acute Lymphoblastic Leukemia
Outstanding work by @LuskinMarlise @DanaFarber @ShaiShimony et al.
ashpublications.org/blood/ar…
Mahasweta Gooptu retweeted
CONGRESS | #ASH2025 | POSTER
Mahasweta Gooptu shares results from a Phase II expansion study focusing on PTCy-based GVHD prophylaxis after MMUD PBSC transplantation with reduced-intensity conditioning (N = 193).
The 1-year OS estimate was 79.6%; rates were comparable between HLA 7/8-matched donor recipients and <7/8 matched donor recipients. The 1-year GRFS, 1-year PFS, 1-year CI rate of NRM, and 1-year CI rate of relapse was 49.9%, 70.2%, 12.5%, and 17.3%, respectively.
Follow our live feed for more updates: loom.ly/MbPzIiA
Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content. A full list of supporters can be found on our website.
#GvHD #GvHDsm #MedEd #MedicalCongress @MGooptu @DanaFarber
Mahasweta Gooptu retweeted
Donor selection guidelines are out! Grateful to have worked with amazing colleagues and the @CIBMTR and @nmdp_org on this effort. Advances in GVHD prophylaxis support moving beyond strict HLA models toward an integrated approach that brings us closer to a suitable donor for every patient. #ADonorForAll #PTCyRules
Just Published in @ASTCT_Journal: Allogeneic Hematopoietic Cell Donor Selection: Contemporary Guidelines from the NMDP/CIBMTR. Read more: sciencedirect.com/science/ar…
Mahasweta Gooptu retweeted
India’s first indigenous CAR-T therapy is now peer-reviewed in @TheLancetHaem , showing a 73% response rate—marking a breakthrough in accessible, cutting-edge cancer treatment.
Mahasweta Gooptu retweeted
Congratulations to @DanaFarber researcher Joseph H. Antin, MD, who received the @ASTCT Lifetime Achievement Award during #Tandem25. He was honored for his ongoing contributions to cellular therapy by advancing scientific knowledge in the field.
Mahasweta Gooptu retweeted
Congratulations to Joseph Antin, MD, recipient of the @ASTCT Lifetime Achievement Award. This recognition is given to a physician who has made continuing contributions to the BMT and cellular therapy fields through the advancement of knowledge through basic or clinical science.
bit.ly/3X05jmp
Mahasweta Gooptu retweeted
Asciminib plus dasatinib and prednisone for Philadelphia chromosome–positive acute leukemia ashpublications.org/blood/ar…
by Dr. Luskin et al. #leusm #ALL
100% CR.
At day 84, 100% of patients achieved complete cytogenetic remission.
At day 84, 74% and 26% achieved BCR::ABL1 reverse transcription quantitative polymerase chain reaction <0.1% and <0.01%, respectively.
Mahasweta Gooptu retweeted
Excited to share our new manuscript co-authored by @DanaFarber BMT mentors Dr. Gooptu (@MGooptu) and Dr. Soiffer:
How I Treat AML relapse after allogeneic HCT:
ashpublications.org/blood/ar…
No one-size fits all approach to this challenging situation, learned a ton writing it!
Mahasweta Gooptu retweeted
🚨 New findings from the @BMTCTN 1703 trial: Post-transplant cyclophosphamide (PTCy) lowers patient-reported #GVHD symptom burden vs Tac/MTX in the first year after transplant. 📊🩺 #PTCyRules Congrats, team!! 💪 @GvHD_Meade @MediHumdani
ascopubs.org/doi/10.1200/JCO…
Mahasweta Gooptu retweeted
🚨Breaking News/Good News from #ASH24🚨
>90% 1-year OS in PTCy-treated alloHCT recipients age 70+ enrolled in @BMTCTN 1703! 😱
Important analysis by @sameem_abedin @MediHumdani @GvHD_Meade and team!! 🙌
ash.confex.com/ash/2024/webp…
#PTCyrules
Mahasweta Gooptu retweeted
🚨Breaking News/Good News from #ASH24🚨
>90% 1-year OS in PTCy-treated alloHCT recipients age 70+ enrolled in @BMTCTN 1703! 😱
Important analysis by @sameem_abedin @MediHumdani @GvHD_Meade and team!! 🙌
ash.confex.com/ash/2024/webp…
#PTCyrules
Mahasweta Gooptu retweeted
In @JCO_ASCO, @DanaFarber @CIBMTR researchers found that using post-transplant cyclophosphamide results in comparable outcomes between HLA-matched & mismatched unrelated donor hematopoietic cell transplants, expanding access for patients of all ancestries. ascopubs.org/doi/10.1200/JCO…
Mahasweta Gooptu retweeted
Replying to @JCO_ASCO @BrianShafferMD
Mahasweta Gooptu retweeted
Wow! This is incredible work that can really open up during our transplantation to many more patients. What a remarkable study!
Remember when we used to avoid mismatched unrelated donor transplants for fear of worse GVHD and NRM outcomes? Those days are over. Congrats to the study team!! 🎉@CIBMTR @nmdp_org @BrianShafferMD @MGooptu @GvHD_Meade @spellman_s @amjimenezmd @DrMonzrAlMalki #PTCyrules
ascopubs.org/doi/10.1200/JCO…
Mahasweta Gooptu retweeted
This is extremely important work supported by @nmdp_org and @CIBMTR. Use of MMUD with PTCy truly means there are donors for all! | PTCy–Based GVHD Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors
ascopubs.org/doi/10.1200/JCO…
Mahasweta Gooptu retweeted
Dana-Farber researchers and faculty made an impressive showing at this year's @ASTCT Meeting
@DanaFarber @MGooptu
oncodaily.com/74915.html
#Cancer #OncoDaily #Oncology #ASTCT #CellularTherapy
Mahasweta Gooptu retweeted
Congratulations to @QingyuLuoMDPhD and our amazing team and collaborators! Tweetorial with more details to come soon... nature.com/articles/s41586-0…
In a recent study published in @Nature, @lane_andy, @QingyuLuoMDPhD and @DanaFarber researchers discovered that a subset of myeloid and lymphoid leukemias depend on a molecular complex called PI3Kgamma for survival.
Press Release ▶️ ms.spr.ly/6018YV100
Mahasweta Gooptu retweeted
Dr. Robert Soiffer, our inspirational leader @DanaFarber, giving the honorific @CIBMTR Mortimer Bortin lecture at #Tandem24 . So well deserved.
Mahasweta Gooptu retweeted
Great session at #tandem24 on alternative donor platforms. PtCy the great equalizer!








































